Biotie Therapies

General Information

We are a biopharmaceutical company primarily focused on developing therapeutics for central nervous system disorders. Our pipeline includes product candidates designed to address unmet medical needs in Parkinson’s disease and related dementia, other neurodegenerative indications and primary sclerosing cholangitis, an orphan fibrotic liver disease. In addition, we have successfully developed a product for alcohol dependence that is being commercialized by Lundbeck and is a source of further potential milestone payments and ongoing royalties.

Employees: 40
Founded: 1998
Contact Information
Address Joukahaisenkatu 6, FI-20520 Turku, Finland
Phone Number +358 2 274 8900
Web Address
View Prospectus: Biotie Therapies
Financial Information
Market Cap $181.9mil
Revenues $10.7 mil (last 12 months)
Net Income $-25.0 mil (last 12 months)
IPO Profile
Symbol BITI
Exchange NASDAQ
Shares (millions): 3.8
Price range $14.89 - $14.89
Est. $ Volume $56.0 mil
Manager / Joint Managers RBC Capital Markets/ Stifel
CO-Managers JMP Securities/ Roth Capital Partners
Expected To Trade: 6/11/2015
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change